

Brazilian Healthcare Biotech Startups Guide



Brazilian Healthcare Biotech Startups Guide

Introducing the Brazilian Healthcare Biotech Startups Guide

In the vibrant landscape of global innovation, Brazil stands as a burgeoning powerhouse in healthcare biotechnology. The **Brazilian Healthcare Biotech Startups Guide** emerges as a seminal work, illuminating the rich tapestry of entrepreneurial spirit, scientific prowess, and groundbreaking advancements that define Brazil's biotech sector. This guide is the fruition of a collaborative effort by Sindusfarma, the Brazilian Pharmaceutical Innovation Network - RBIF, and Biominas Brasil, showcasing a diverse ecosystem thriving on creativity, multidisciplinary approaches, and a relentless pursuit of solutions that promise to redefine healthcare, both locally and globally.

Brazil's biotechnological landscape is as diverse as its ecosystem, boasting startups that span the healthcare spectrum – from novel drug discovery and diagnostics to advanced therapies and digital health innovations. These ventures not only reflect the country's rich scientific heritage and robust research infrastructure but also underscore a commitment to addressing some of the most pressing health challenges of our time.

A Gateway to Global Biotechnology Ecosystems

The **Brazilian Healthcare Biotech Startups Guide** serves not just as a directory but as a beacon for global stakeholders in the biotech domain. It offers a panoramic view of Brazil's biotechnological innovations, investment landscapes, and regulatory frameworks, making it an invaluable resource for investors, researchers, and policymakers keen on tapping into Brazil's biotech potential or forging synergistic partnerships.

Through comprehensive profiles and analyses, the guide highlights the vibrancy of Brazil's biotech startups, their areas of expertise, and their contributions to global health challenges. It underscores the pivotal role these entities play in fostering a sustainable, innovative, and health-focused future.

Embracing the Future

As we stand on the cusp of a biotechnological renaissance, the **Brazilian Healthcare Biotech Startups Guide** is more than just a compilation; it is a testament to Brazil's readiness to be a global leader in health innovation. It celebrates the spirit of discovery that drives our biotech startups, their resilience in the face of challenges, and their vision for a healthier world.

We invite you to delve into this guide, discover the untapped opportunities within Brazil's biotech ecosystem, and join us in

forging a future where innovation, collaboration, and health equity are paramount. Welcome to the forefront of health-care biotechnology in Brazil.

Rosana Mastellaro, Sindusfarma

Marcio de Paula, Sindusfarma consultant

Eduardo Emerich, Biominas Brasil

Fortifying Brazil's Position in the Global Health Biotechnology Landscape

Brazil's journey in the realm of healthcare biotechnology is distinguished by its robust ecosystem of innovation, deeply rooted in the rich scientific heritage and diverse biological resources unique to the country. The **Brazilian Healthcare Biotech Startups Guide** emerges as a pivotal initiative, conceived by the Brazilian Pharmaceutical Innovation Network - RBIF, Sindusfarma, and Biominas Brasil. This comprehensive guide aims to spotlight Brazil's dynamic biotech sector, showcasing its capacity to contribute significantly to the global health innovation narrative.

This guide is born out of a recognition of Brazil's strategic position as a leader in biotechnological innovation within Latin America and its potential on the world stage. It serves as a crucial conduit for fostering national and international collaborations, highlighting the innovative prowess of Brazilian startups, and drawing attention to investment opportunities within the sector. By cataloging the diverse range of biotechnological solutions in healthcare provided by Brazilian startups, the guide endeavors to facilitate



constructive dialogues and partnerships across the global biotech community.

Brazil's biotechnology sector benefits from a confluence of factors: a rich biodiversity that is unparalleled, a strong academic and research foundation, and a vibrant startup ecosystem that is increasingly attracting domestic and international investment. The country has demonstrated remarkable progress in areas such as drug discovery, diagnostics, bioinformatics, and personalized medicine, leveraging its unique resources and scientific talent.

Moreover, the guide reflects on the importance of collaboration among the various stakeholders within the biotech ecosystem, including universities, research institutions, government agencies, and the private sector. It emphasizes the role of synergistic partnerships, such as the ones between RBIF, Sindusfarma, and Biominas Brasil, in driving forward the nation's biotechnological advancements and reducing barriers to innovation and market entry.

The **Brazilian Healthcare Biotech Startups Guide** not only aims to showcase the current state of the sector but also to inspire future innovation and growth. It is designed to be an invaluable resource for startups seeking visibility, investors looking for promising opportunities, and international partners interested in engaging with Brazil's biotech landscape.

As Brazil continues to solidify its status as a key player in the global biotechnology domain, this guide stands as a testament to the country's innovation capabilities, its commitment to healthcare advancement, and its potential for driving significant global impact through biotechnological solutions.



The **Brazilian Healthcare Biotech Startups Guide** facilitates the construction of collaborations and business opportunities by bringing together startups, investors, service providers, and pharmaceutical industries of the most diverse biotechnology solutions in health. Furthermore, as a result of the synergistic partnership between RBIF, Sindusfarma, and Biominas Brasil, the Brazilian Healthcare Biotech Startups Guide makes it possible to reduce geographical distances by promoting the exchange of knowledge between a country as vast and diverse as Brazil and other countries.


Methodology: Gathering Insights from Brazil's Biotech Innovators



The foundation of the **Brazilian Healthcare Biotech Startups Guide** is built upon direct contributions from the heart of Brazil's biotech innovation ecosystem: the startups themselves. Through a meticulously designed survey, we engaged with 69 biotechnology startups across the nation, inviting them to share detailed insights about their operations, challenges, and visions for the future.

This initiative's methodology was tailored to delve deep into the dynamics of Brazil's biotech sector, aiming to capture a comprehensive snapshot of current market trends, the operational excellence of startups, and their strategic outlook towards globalization. The survey encompassed a wide range of questions designed to uncover the startups' perspectives on market needs, innovation capabilities, and readiness for international collaboration.


By harnessing the firsthand experiences and data shared by the startups, the guide aims to provide an authentic portrayal of Brazil's biotech landscape. This includes an exploration of the startups' core competencies, their contributions



to the health sector, and their strategies for navigating the complexities of going global. This approach ensures that the guide serves as an invaluable resource for stakeholders interested in understanding and engaging with Brazil's vibrant biotech ecosystem.

Through this methodology, the **Brazilian Healthcare Biotech Startups Guide** not only showcases the potential and achievements of individual startups but also highlights the collective strength and innovative spirit of Brazil's biotech sector. This initiative stands as a testament to the collaborative effort to propel Brazil onto the global stage of biotechnology innovation, fostering connections, and driving forward the nation's contributions to global health advancements.


Overview of Key Findings: Trends and Opportunities in Brazilian Healthcare Biotechnology



This segment of the **Brazilian Healthcare Biotech Startups Guide** is dedicated to uncovering the overarching patterns and prospects that define the biotech sector in Brazil. Through a detailed analysis of the input received from the nation's pioneering biotech startups, we aim to provide a comprehensive look at the current state and future directions of healthcare biotechnology in Brazil.

It's important to note the diversity in response types facilitated by our survey design, which included both single-option and multiple-option queries. This approach allowed us to gather nuanced insights into the startups' operations, strategies, and perspectives. Consequently, some topics garnered responses that exceed the count of participating startups, reflecting the multifaceted nature of their experiences and plans.


By dissecting these findings, we strive to present a clear picture of the vibrant ecosystem that is Brazil's healthcare biotech sector, emphasizing not only the trends that are shaping its evolution but also the opportunities that lie ahead



for innovation, collaboration, and growth. This analysis is intended to serve as a valuable resource for stakeholders within and beyond Brazil, looking to engage with and contribute to the advancement of healthcare biotechnology on a global scale.

1. Operational Analysis Across Key Sectors

In the inaugural edition of the Brazilian Healthcare Biotech Startups Guide, we aimed to thoroughly map startups within the healthcare sector. However, given the interdisciplinary nature of biotechnology, our exploration extended into how these startups intersect with and impact additional sectors. This examination is premised on the understanding that a startup, while primarily focused on healthcare solutions, might also have significant implications for sectors such as environmental sustainability or agriculture. By adopting this broader lens, we are able to highlight the extensive diversity and cross-sectoral integration within the operational areas of these startups, underscoring the wide-ranging influence of biotechnological innovations across various domains.




2. Sectoral Insights and Innovations: An Analytical Overview

The **Brazilian Healthcare Biotech Startups Guide** presents a detailed analysis of the vibrant landscape of health biotechnology startups, focusing on the diversity of solutions they offer and the healthcare areas they target.

Solutions Spectrum

Our findings reveal a significant emphasis on analysis and diagnosis within the startups featured in the Guide. A total of 35 solutions were identified in this category, making it the most represented area of focus. Following closely, the domain of Pharmaceuticals, Therapies, and Chemicals was highlighted by 27 startups, illustrating a strong inclination



towards drug development and chemical solutions. The service sector also stood out, with 19 startups dedicating their efforts to enhancing healthcare services through innovative approaches.

Areas of Prominence

In delving deeper into the solutions provided by these startups, we unearthed key areas of expertise that hold promising potential for future development:

- Wellbeing and Aging
- Dermatology
- Medical Devices
- Chronic Diseases
- Neglected Diseases
- Rare Diseases
- Genetics
- Oncology
- Digital Technologies, including Cloud Computing, Artificial Intelligence, and Geoprocessing


Noteworthy is the attention drawn to neglected diseases, where a growing trend in the development of diagnostic kits leveraging novel molecular methodologies was observed. This includes biotechnological advancements aimed at creating enhanced therapeutic strategies, notably in the fight against Leishmaniasis—a critical public health concern in Brazil.


The field of rare diseases has seen considerable efforts, particularly in industrial biotechnology, where bioengineering

and stem cell technologies are being explored. The genomics area is also gaining traction, highlighted by the application of CRISPR gene-editing technology, offering new avenues for addressing diseases affecting a minor segment of the population.

Oncology presents a detailed exploration of precision medicine, pharmaceutical interventions, and algorithmic solutions, indicating a convergence of technologies aimed at overcoming challenges in cancer treatment.

3. Distribution of Startups by Regional Presence within Brazil






The geographic analysis of startup locations within the Brazilian Healthcare Biotech Startups Guide reveals a distinct concentration of activity across different regions of the country, showcasing the diversity and regional strengths within the biotech sector:

- **Southeast:** Dominates with 64.1%, underscoring its role as a central biotech hub, particularly in major cities such as São Paulo, Belo Horizonte, and Rio de Janeiro.
- **South:** Follows with 14.1%, indicating a significant presence and growing biotech ecosystem.
- **Northeast:** Holds a considerable share at 9.4%, highlighting emerging opportunities and developments.
- **Midwest:** Accounts for 7.8%, showcasing its evolving role in the national biotech landscape.
- **North:** Although smaller at 4.7%, represents vital emerging opportunities within the sector.

This distribution emphasizes the Southeast region's pivotal role in fostering a thriving biotechnological environment, with São Paulo, Belo Horizonte, and Rio de Janeiro being key players. The data reflects not just regional disparities but also the potential for growth and expansion across Brazil's diverse ecosystems, indicating a robust and expanding foundation for biotech innovation throughout the country.

4. Investment Landscape for Healthcare Startups in Brazil



7,9%	Awards
2,38%	Corporate Venture Capital
10,3%	Angel investment
7,1%	Venture Capital
30,2%	Public funding
28,3%	Bootstrapping/Own resource
18,26%	Other Private investments


An examination of the funding sources for Brazil's healthcare startups reveals a diverse mix of public and private investment channels:

- **Public Funding:** Emerges as the most prevalent source, with 30.2% of startups benefiting from governmental support.

- **Bootstrapping/Own Resource:** Close behind at 28.3%, indicating a significant degree of self-financing among entrepreneurs.
- **Other Private Investments:** Account for 18.26%, showcasing a variety of alternative private funding mechanisms.
- **Angel Investment:** Represents 10.3%, highlighting the role of individual investors in supporting early-stage startups.
- **Awards:** Contribute to 7.9% of funding, underscoring the impact of competitive grants and prizes.
- **Venture Capital:** Also plays a key role, funding 7.1% of startups, signaling growing interest from institutional investors.
- **Corporate Venture Capital:** Though smaller at 2.38%, indicates increasing corporate interest in the sector.

This investment overview suggests a cautiously optimistic environment for Brazil's healthcare startups, characterized by a burgeoning yet reserved influx of capital. Recent trends indicate that investors are beginning to commit more substantial funds, drawn by the high quality of Brazilian startups, the vast market potential, and relatively lower costs of development. The anticipated growth in venture capital engagement is poised to yield encouraging outcomes in the near future, further energizing Brazil's position as a promising landscape for healthcare innovation and investment.

5. Revenue Strategies within Brazilian Healthcare Biotech Startups




The **Brazilian Healthcare Biotech Startups Guide** sought to understand the preferred revenue models of the participating startups, alongside the strategic considerations driving these choices:

- **Business-to-Business (B2B):** Leads with 51.9%, indicating a primary focus on direct sales to other businesses.
- **Business-to-Business-to-Consumer (B2B2C):** Follows with 18.87%, reflecting a model where startups partner with businesses to reach end consumers.
- **Direct-to-Consumer (B2C):** Accounted for by 15.09% of startups, highlighting a strategy of selling directly to the consumer market.

- **Business-to-Government (B2G):** Represents 6.60%, showcasing those startups engaging directly with government agencies.
- **Software as a Service (SAAS):** Captures 2.83%, pointing to a subscription-based software delivery model.
- **Business-to-Business-to-Government (B2B2G):** Is the least common, with 1.89%, involving transactions from businesses to the government via another business.
- **Other Revenue Models:** Comprise 1.88% of responses, indicating niche or alternative approaches.

This distribution of revenue models sheds light on the varied approaches Brazilian healthcare biotech startups are employing to monetize their innovations. The preference for B2B transactions underscores the sector's inclination towards leveraging business partnerships, while the significant representation of B2B2C and B2C models illustrates diverse market engagement strategies. Collectively, these insights into revenue models reveal a dynamic landscape of business strategies tailored to the unique opportunities within the Brazilian healthcare biotech ecosystem.

6. Strategies for Global Expansion among Brazilian Healthcare Biotech Startups




The **Brazilian Healthcare Biotech Startups Guide** delved into the internationalization strategies favored by startups, aiming to discern patterns in their global outreach efforts:

- **Co-development Partnerships:** Emerge as the preferred strategy, with 45.90% of startups identifying it as a key avenue for international expansion. This approach indicates a strong inclination towards collaborative development projects with international partners.
- **Direct Investment:** Follows closely, with 32.79% of startups viewing it as an effective method for entering foreign markets, underscoring the value placed on establishing a direct presence overseas.

- **Internationalization to Switzerland:** Is highlighted by 11.48% of startups, reflecting a specific interest in the Swiss market due to its robust biotech ecosystem.
- **Exportation:** Is considered by 6.56% of respondents, suggesting a focus on selling products or services directly to overseas markets.
- **Joint Ventures:** Are least favored, with 3.28% of startups considering it as a strategy, indicating a cautious approach to sharing business ownership with international entities.

Out of the 69 startups surveyed, a significant proportion signaled a preference for co-development partnerships as a pathway to global market entry. This preference suggests that collaborative innovation is seen as a vital strategy for scaling and accessing new markets. Direct investment also emerged as a noteworthy strategy, highlighting the startups' willingness to commit resources to establish a foothold in international markets directly.

7. Development Phases of Companies within the Brazilian Healthcare Biotech Startups Guide




The **Brazilian Healthcare Biotech Startups Guide** includes a focused section on the technological development stage of each participating startup, using the Technology Readiness Levels (TRL) as a framework. This approach offers a nuanced understanding of each technology's stage of development, from initial research to full commercialization.

- **Validation Stage:** A significant 54.93% of startups are in the validation phase, where their technologies undergo rigorous testing to confirm that their foundational principles work under specified conditions. This includes both laboratory testing and validation in environments relevant to their intended market application.

- **Traction Phase:** The next largest group, 19.72% of startups, are in the traction phase, where their products or services begin to gain steady acceptance and increased use in the market, signaling early stages of growth and customer adoption.
- **Scale-up Phase:** Close behind, 18.31% of startups have reached the scale-up phase. At this advanced stage, technologies are fully developed, with models and prototypes having been tested and validated in actual environments.
- **Ideation Phase:** The smallest segment, 7.04%, is still in the ideation phase, focusing on conceptualizing and exploring potential technological solutions. This early stage involves brainstorming and the preliminary exploration of feasible concepts.

Across the 69 startups that participated, the prevalent focus on the validation stage underscores a commitment to ensuring that their innovations are robust, effective, and ready for the next steps toward commercialization. The presence of startups at various stages of development reflects a dynamic and maturing ecosystem, with technologies ranging from conceptual ideas to those ready for market expansion and growth.

Startup Profiles Overview



This section presents a comprehensive listing of the startups that participated in the survey for the **Brazilian Healthcare Biotech Startups Guide**. Detailed within are the foundational elements of each startup, including general information, the status of their intellectual property, current investment phases, and contact details via their websites. For this section we included only startups mainly focused on the healthcare biotech segment.

For more detailed information about the startups and contact information, contact Biominas Brasil through the email: biominas@biominas.org.br



3D BioNano Research and development LTDA

Founded in 2023, 3D BioNano is a startup that offers solutions within the healthcare sector featuring innovative bandages driven by nanotechnology and cutting-edge science.

Website:

www.3dbionano.com.br

Solution/Product:

Development of a bandage made of biocompatible and biodegradable polymeric nanofibers manufactured using electrospinning and 3D printing. The dressing contains broad-spectrum antimicrobials, which fight infections and accelerate wound healing.

Intellectual property:

Patentable by copyright

Region of the country:

Northeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



AIPER

Based on research, in the laboratory, to optimize the culture medium and growth conditions of a bacteria that produces biopigments, AIPER was created as a biotechnology startup that researches and develops microbial biopigments from agricultural waste, promoting the circular bioeconomy.

Website:

www.aiper.com.br

Solution/Product:

AIPER develops biopigments of microbial origin for application in industry, being produced from fermentative processes using agricultural waste as a nutritional source. These biopigments have various biological activities, such as bactericidal and antiviral activities, among others.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million

Alfa Biotechnological Adhesives

The startup, founded in 2020, has as its main activity Experimental Research and Development in Physical and Natural Sciences. The startup participated in the Centelha Program, where it obtained about ten thousand dollars in investment.

Website:

Does not have

Solution/Product:

The startup presents a solution based on the manufacture of a product used to heal chronic and post-operative wounds against skin cancer.

Intellectual property:

Can be patented by copyright or utility model

Region of the country:

Midwest

Current round of investment:

The startup is not looking for investments at the moment



BioDecision Analytics Ltda.

BioDecision Analytics' mission is to integrate different areas of knowledge with regulatory standards to provide smart solutions to laboratories and (bio)pharmaceutical industries, extracting value from data and enhancing research, development and innovation (RD&I) results for investigational products.

Website:

www.biodecisionanalytics.com

Solution/Product:

BioDecision Analytics has a range of activities in its portfolio, such as solutions for the pharmaceutical sector, technical consultancy in Analytics and Bioinformatics for pharmaceutical entities and Health Techs, as well as scientific and regulatory consultancy.

Intellectual property:

Can be protected by utility model, trade secret or software registration

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



BIOSCIENT

Bioscient is a startup committed to innovation in the drug discovery process. The startup also works with technology transfer in the areas of research and development of medicines with a view to training human resources in the areas of bioinformatics and biotechnology.

Site:

www.linkedin.com/company/bioscient/

Solution/Product:

The startup developed a web tool that can filter, among thousands of molecules, those that have pharmaceutical potential for the development of a new cancer drug. The tool can be customized for any disease, it just needs the data, which can be private or come from public banks.

Intellectual property:

Can be protected by software registration

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investments at the moment

biosens

Biosens Development and industry of biosensors

Biosens is a deep tech company of life sciences that operates in the research, development, production and commercialization of biosensors. There are three areas that distinguish and differentiate its vision in catalyzing changes in healthcare: biotechnology, MedTech and semiconductor and advanced materials.

Website:

www.biosens.tech

Solution/Product:

The technological platform developed, called bSens, is made up of three of the startup's solutions. These solutions involve equipment and devices, cloud system for data storage and biological testing devices. In addition to these, there are four other products in the *roadmap* from Biosens, all evaluated based on the demands of healthcare professionals.

Intellectual property:

Can be patentable by utility model

Region of the country:

South

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



BiotechnoScience

BiotechnoScience Farmacêutica LTDA

Founded in 2021, with the aim of developing new products for use in the dermatological area, in pharmaceutical and cosmetic segments.

Website:

www.bsfarmaceutica.com

Solution/Product:

The formulation developed as a cream contains the compound ingredient in very low concentrations, which were effective in wound healing with excellent action in tissue regeneration and remodeling, with significant collagen production and absence of keloids.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



Biozeus Biopharmaceutical SA

Biozeus was founded in 2012 to bridge the gap between the discovery stages and the market. Biozeus is supported by a Brazilian venture capital company. Its infrastructure and financial management are built on the scientific and commercial expertise needed to identify, license and develop promising drug discoveries in humans.

Website:

www.biozeus.com.br

Solution/Product:

Biozeus is a clinical-stage biotechnology company focused on developing new medicines from discovery and initial testing, through preclinical development (animal studies) through the clinical stage (human studies). Once we reach the desired development stage, we license the project to pharmaceutical and biotechnology companies around the world who will commercialize the technology.

Intellectual property:

Can be patentable by copyright

Region of the country:

Southeast

Current round of investment:

Series A

Value that the startup is seeking:

Above US\$ 2 million



Chimera Diagnostics - High-performance proteins for immunodiagnosis

Chimera Diagnósticos was born from the visualization of the demand for the national production of antigens for immunodiagnostic kits.

Website:

www.linkedin.com/company/chimera-diagnósticos

Solution/Product:

The startup intends to produce antigens, with 100% national origin, improving the distribution logistics, price and effectiveness of national kits.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



DNA Club

The startup believes in a version of health with more autonomy, based on disease prevention and prioritizing healthy habits. The health ecosystem aims to match genetic needs with products and services.

Website:

www.dnaclub.com.br

Solution/Product:

DNA Club uses bioinformatics algorithms to identify health predispositions and connect our customers to products and services personalized according to their DNA. The startup customizes results according to the needs of its partners (B2B2C or B2C) and offers a Healthcare Ecosystem Platform for its B2C and D2C customers.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investments at the moment



DruGet

DruGet aims to reduce the time and monetary value spent on discovering solutions using computational analysis services to select the most promising molecules for the laboratory solution. In addition to innovative technology and consulting services, DruGet offers specialized training in ADMETox.

Website:

www.druget.com.br

Solution/Product:

The startup offers a platform that is capable of integrating safety and efficacy analyzes of new molecules with a 97% reduction in time and 80% in cost in one of the stages of the process to reach the market, meeting the immediate needs of the pharmaceutical and agrochemical industries and chemistry.

Intellectual property:

Can be patented by software registration

Region of the country:

North

Current round of investment:

The startup is not looking for investments at the moment



Fly2Human

The Fly2Human is a biotechnology platform for functional screening that can accelerate translation into therapeutic strategies with innovative solutions for neurodegenerative diseases, including ALS.

Website:

Solution/Product:

Functional screening uses *D. melanogaster* containing patient-specific human mutations and human induced pluripotency stem cells (iPSCs) to validate gene variants derived from WGS and WES potentially associated with neurodegenerative diseases and discover new genes with neuroprotective potential.

Intellectual property:

Can be patented by utility model

Region of the country:

Midwest

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



Gcell 3D cultivation

Founded in 2019, Gcell Cultivo 3D is a Research & Development startup that produces technology with potential for innovation in the biotechnology segment, specialized in 3D cell cultivation. The company's main objective is to promote Humanized 3D (R)evolution for the area of drug development and testing and regenerative medicine. Our scalable technology for the formation of 3D tissue equivalents is based on spheroid cultivation.

Website:

www.gcell3d.com

Solution/Product:

Gcell's technologies are based on the manufacture of tissues and organs in the laboratory that mimic native ones. These 3D models can be applied in the pharmaceutical industry for the discovery and testing of medicines and in the prosthetics industry as alternatives for medical transplantation.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investment at the moment



Gentros Research and Development Ltd

In mid-2012, with the emergence of international human metagenomics consortia, the company focused on the effectiveness of pre-biotics and probiotics, based on metagenomics involving partner companies, such as clinical testing companies to test the effectiveness of products on our microbiota. Currently, 15 years later, Gentros works in partnership with clinical testing companies to test the influence that a certain product has on the collected microbiota, what interaction and whether it brings benefits to the user.

Website:

www.gentros.com.br

Solution/Product:

Gentros is a biotechnology laboratory with services aimed at the pharmaceutical, veterinary, cosmetic, food and agricultural markets. To this end, they use state-of-the-art equipment to carry out sequencing on NGS platforms (Illumina and Nanopore).

Intellectual property:

Non-patentable solution

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investment at the moment



Glia Innovation

Glia Innovation has a focus on disruptive innovation and technological development. Its mission is to create active ingredients for high-performance, value-added cosmetics. Furthermore, it employs several nanotechnology platforms and uses the bio-design of very high quality biomimetic peptides, always being in tune with the market's leading technologies.

Website:

www.gliai.com.br

Solution/Product:

Glia Innovation presents nano and biotechnological raw material solutions for the cosmetics and agribusiness industries.

Intellectual property:

Patent already deposited

Region of the country:

Midwest

Current round of investment:

Bootstrapping/no external investment

Value that the startup is seeking:

The startup is not looking for investment at the moment



Huna IA

Huna aims to democratize and optimize the early diagnosis of prevalent cancers and chronic diseases, directly facing the challenge of the high cost and complexity of traditional diagnostic journeys.

Site:

www.huna-ai.com

Solution/Product:

The solution, an advanced digital platform, uses Artificial Intelligence to analyze blood test results, complementary reports and clinical reports, identifying risk patterns for chronic diseases and multiple cancers in an efficient and economical way.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Series A

Value that the startup is seeking:

Above US\$ 2 million

ImmunoTera

ImunoTera was founded in 2016 with the purpose of transforming scientific research into health solutions for society. The startup was founded by three researchers who develop therapeutic vaccines against infectious diseases and some types of cancer.

Site:

www.imunotera.com.br

Solution/Product:

The company's first focus is the treatment of cancer caused by HPV, such as cervical cancer and head and neck cancer, which affects more than 1 million people worldwide every year.

Intellectual property:

Patent already deposited and granted.

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



In Situ Cell Therapy

In Situ is a technology-based startup in the health sector, which uses cell therapy as a tool for creating innovative products.

Site:

www.insitu.com.br

Solution/Product:

Currently, In Situ Terapía Celular has three products in the R&D phase: the 3D bio dressing containing stem cells, intended for the treatment of chronic wounds and severe burns, the extracellular nano-vesicle ointment intended for the treatment of less complex wounds and scars and the 3D biograft intended for the treatment of gingival recession.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



In Vitro Cells Toxicological Research LTDA

The startup has cutting-edge research technology in the areas of Life Sciences and Aging. With a Technological Platform focused on the future and being applied today, IVC is the first company to develop projects in Brazil in the area of Subclinical Chronic Inflammation, Oxidative Stress and Cellular Aging, all through its IN VITRO methodology.

Site:

www.ivchealth.com.br

Solution/Product:

In Vitro Cells works with a new technology that evaluates early markers of subclinical chronic inflammatory processes and oxidative stress using a cellular environment that is different from the assessments offered on the market that use serum or plasma. The big difference is that all the markers of these processes are not found in serum or plasma but in cells.

Intellectual property:

Patent already deposited and granted

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investment at the moment



Inpreha Biotechnology and Advanced Development S.SA

Inpreha Biotechnology is a technology-based and innovation company focused on the animal reproduction sector, with a line of products for large and small animals. It has a history of R&D and innovation in the startup's routine, being awarded economic subsidy projects by research funding bodies such as FAPESP, FINEP and CNPq.

Site:

www.inpreha.com.br

Solution/Product:

Veterinary product, already registered in Brazil for cattle, based on recombinant protein, which increases the chances of pregnancy in mammals, and can be used as a tool to increase productivity in livestock farming. The technology is patented in 16 countries covering mammals in general. For humans, it can be used as a supplement to increase the chances of pregnancy in assisted reproduction procedures.

Intellectual property:

Patentable, already granted

Region of the country:

Southeast

Current round of investment:

Series B

Value that the startup is seeking:

Above US\$ 5 million



JO+ Dermal Absorbent

The product is an innovative solution in response to an existing opportunity in the market. The dermal pad is a product that allows better absorption and hygiene. Additionally, with small constructive adjustments, the product will meet an important demand and need for use in orthopedics, absorbing and isolating wounds treated with invasive metal devices.

Site:

www.absorventedermico.com.br

Solution/Product:

The Dermal Absorbent isolates the skin from the device, avoiding pressure, rashes, and absorbs liquids (gastric juice, water, medications and food) that leak from the stoma. The solution avoids contact with the skin in the abdominal region, eliminating diaper rash, odors, bleeding and opportunistic infections, cross-infections in hospital units and home care. This reduces waste of financial resources, hospital materials and medical waste.

Intellectual property:

Can be protected by utility model

Region of the country:

Northeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



Mirscience Therapeutics

Mirscience Tx develops RNA molecules for the treatment of chronic muscular and metabolic diseases. It is a biotech that develops RNA therapy for the treatment of muscle diseases that impact longevity.

Site:

www.mirsciencetx.com

Solution/Product:

Mirscience has a Platform (Mir-Discovery) that analyzes thousands of genomic data, identifies the main targets responsible for diseases and develops RNA molecules that act in a specific way, developing a new era of precision therapy.

Intellectual property:

Patentable, already registered as an industrial secret.

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



OncoTag

OncoTag is dedicated to translational and pharmacogenetic research. Explores the connections between basic research and clinical application, as well as advances in personalizing treatments based on individual genetics.

Website:

www.oncotag.com.br

Solution/Product:

Artificial intelligence platform based on molecular markers to evaluate response to treatment and prognosis of patients with colorectal cancer.

Intellectual property:

Patentable, can be protected by utility model

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investments at the moment



Ostera

Ostera develops solutions to improve the success rates of assisted reproduction techniques and products that can make women more empowered in their reproductive future.

Site:

www.ostera.co

Solution/Product:

OsteraTest, developed by Ostera, is its own, innovative and patented technology, and is the only test on the market that makes it possible to identify the potential of eggs to become high-quality embryos.

Intellectual property:

Patentable, can be protected by software registration

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



PepLab

PepLab is a biotech company for research and prospecting of bioactive peptides in human, animal or plant biological fluids, to discover candidates with some industrial or pharmaceutical interest.

Site:

Solution/Product:

To carry out its prospecting activities, the startup uses the mass spectrometry technique to identify differences in peptide content by comparing control (non-disease) and experimental (disease) samples. Based on the differences found, we carry out a study with database searches to prospect candidate peptides that can be synthesized and characterized in the laboratory regarding their possible biological functions.

Intellectual property:

Patentable, can be protected by software registration

Region of the country:

North

Current round of investment:

The startup is not looking for investment at the moment



PROBES - Research, Innovation and Technological Development

DermoPROBES is a company specialized in clinical analysis for cosmetics, pharmaceutical products and non-invasive skin tests. Using the confocal Raman spectroscopy technique, we perform efficacy testing services for cosmetic products, as well as prepare projects to be submitted to government funding agencies, maximizing our customers' access to non-refundable financial resources.

Site:

www.dermoprobes.com

Solution/Product:

Cosmetic and dermocosmetic efficacy tests, and drug formulation.

Intellectual property:

Patentable

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



REPAIRNANOTECH

Site:

Solution/Product:

The solution is a drug (collagen biogel associated with protein and gold nanoparticles) applied topically or subcutaneously that reduces the repair time for skin wounds, reducing inflammation and providing better aesthetics.

Intellectual property:

Patentable, already deposited

Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



Ridepeps: Nanocarrier peptides for optimizing health therapies

Site:

www.ridepeps.wixsite.com/my-site

Solution/Product:

Ridepeps presents a disruptive solution by proposing the transport of drugs into cells using a snake toxin. In this way, there will be an increase in pharmacological efficiency within the cell (lower concentration of drugs) and a reduction in possible side effects considering in vivo therapy.

Intellectual property:

N/A

Region of the country:

Northeast

Current round of investment:

The startup is not looking for investment at the moment



Human Cell and
Tissue Engineering

Biocelltis Biotechnology/Advanced Biomaterials

Based on a sustainable approach throughout the production chain, the startup stands out for its innovation in the production of advanced biomaterials, especially aimed at the pharmaceutical, cosmetic and veterinary industries.

Site:

www.biocelltis.com

Solution/Product:

Products from the CellFate line, such as the CellFate® 3D matrix, made up of natural polymeric nanofibers, have a wide range of applications in tissue engineering, regenerative medicine and stem cell research. These biomaterials, similar to human collagen, are biocompatible, sterile and ready-to-use, providing an ideal environment for growing human and animal cells and tissues in the laboratory.

Intellectual property:

Patentable, already deposited

Region of the country:

Southeast

Current round of investment:

Series A

Value that the startup is seeking:

Above US\$ 2 million



Living Out - in vitro testing

Founded in 2019, made up of experts in 3D cell cultivation techniques, the startup's focus is currently on generating 'minitumors', tumor organoids derived from patients, which can be applied in different areas.

Site:

www.livingout.com.br

Solution/Product:

Living Out's solution consists of a personalized oncology medication selection service that provides oncologists with better assertiveness when making decisions regarding patient treatment. This selection is carried out through in vitro sensitivity assays using the patient's own cells that are maintained in the laboratory using the technique of cultivating patient-derived tumor organoids (PDTO) or, simply, mini-tumors.

Intellectual property:

May be protected by industrial secret

Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



R&R NOVABIO OCULAR

The Startup was born from the passion for inventive entrepreneurship that its co-founders carry in their DNA, from the inspiration experienced in Boston and from the freedom to create found during their Post-Doctorate in the Department of Ophthalmology at Harvard Medical School. R&R NOVABIO's main purpose is to transform science into products with social impact (improving people's quality of life) and economic impact (our country as a technology generating hub).

Site:

www.renovabioocular.com

Solution/Product:

R&R NOVABIO OCULAR works to develop new therapeutic and diagnostic options for AMD. The startup developed 2 prototypes of small molecule pharmaceutical composition to be delivered via eye drops, 1 for each form of the disease. Preclinical studies are underway to verify efficacy and toxicity. The startup also identified 2 prototypes of blood biomarkers in the pre-clinical phase for dry AMD and 2 prototypes for the neovascular form sensitive to changes in pathogenesis. The next step will be validation with patient samples.

Intellectual property:

Patent already deposited



Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



Bioshield LTDA

The startup focuses on creating world-class development and manufacturing capabilities for advanced biologic therapies and vaccines in Latin America. Your mission is to empower Latin America (and the southern hemisphere) to combat current and future diseases, biological threats and pandemics.

Site:

www.bioshield.co

Solution/Product:

BioShield(SM) is building Latin America's first large-scale, next-generation advanced biologics Manufacturing Development Organization (CDMO). Upon successful completion of its first factory, the company will create the infrastructure necessary for Latin America to truly participate in the new Global Era of Biology. BioShield's platform will unlock Latin America's potential to be self-sufficient in providing its regional bioprotection and to support the future global response to biological threats such as pandemics, epidemics and bioterrorist attacks.

Intellectual property:

Can be protected by industrial secret and utility model

Region of the country:

Southeast

Current round of investment:

Series A

Value that the startup is seeking:

Above US\$ 2 million



RioGen

RioGen is working on the development of a molecular urine test to detect prostate cancer, which can be used to screen patients, indicating the need or not to perform a conventional biopsy (invasive, painful and high cost).

Site:

www.riogen.com.br

Solution/Product:

The solution consists of a molecular urine test, which evaluates the expression of a panel of genes associated with prostate cancer, through qPCR technology, identifying the need for a biopsy. Our gene panel was selected through a careful biomarker prospecting analysis, applying bioinformatics and machine learning methods, allowing us to generate genetic signatures, capable of identifying the probability of malignancy.

Intellectual property:

Patentable

Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



R-Crio Stem Cells, Bioengineering and Development of Biological Medicines

The R-Crio laboratory is a Cellular Processing Center. This means that, in addition to being qualified to cryopreserve, we are also qualified to process and prepare stem cells for clinical use in people. Since the laboratory was founded in 2014, we have brought the highest global quality standards in stem cell storage, as well as values focused on transparency and quality above all else.

Site:

www.r-crio.com

Solution/Product:

Cell Processing Center and development of biological medicines (Advanced Therapy Products) from Mesenchymal Stem Cells and new cellularizable bioengineered materials for use in Regenerative Medicine, aiming to combat degenerative and inflammatory diseases and accidents (fractures, burns) from of the medicinal potential of mesenchymal stem cells processed and qualified in a GMP laboratory for the purpose of autologous or allogeneic use, with production reproducibility on an industrial pharmaceutical scale.

Intellectual property:

Patent already deposited

Region of the country:

Southeast



Current round of investment:

Series B

Value that the startup is seeking:

Above US\$ 5 million



Nefront RD&I in Biotechnology and Microfluidics

Nefront seeks to be in tune with trends in the Kidney-on-chip (OoC) market, responding to pressing demands, not yet met by the national market, from researchers, industry and market drivers, with an attractive value proposition. They use cutting-edge, emerging technology with great global impact with a disruptive business model, providing the startup with recurring revenue in a market still in its infancy (blue sea) nationwide.

Site:

Solution/Product:

Our biotechnological product (and service) consists of a three-dimensional in vitro microphysiological system (MPS) (organ-on-a-chip | OoC), used as an investigational technological platform, in a controlled microenvironment, which recapitulates one or more relevant aspects of the dynamics, functionality and physiological response of the organ in vivo and biomarker profile in vitro, under real-time monitoring. Throughout the long-term project, we will co-culture primary cells from the human proximal tubule (kidney), podocytes and endothelial cells, recreating an important part of the filtration and excretion of human kidney tissue.

Intellectual property:

Patentable



Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000

ProSource Biotechnology Ltd

ProSource Biotechnology operates in the planning, development, production and testing of proteins as products, inputs and biotechnological tools. With our experience in Research and Development, we work to find processes that are reliable and reproducible to obtain the target protein.

Site:

www.prosourcebio.com

Solution/Product:

The universe of proteins allows us to apply these molecules in various fields of health and technology. In all these possibilities, to achieve a good quality protein, the unique characteristics of each target and its production steps must be carefully analyzed. The company presents the proposal for a platform for the development of national technologies, reducing costs and making it possible to meet the country's and Latin America's own demands. ProSource Biotechnology fits into the CRO (Contract Research Organization) company model and works together with other companies and institutions in the creation, research and development of new products and technologies in biosciences. Our purpose is to understand the challenges and join forces in the search and construction of new solutions.

Intellectual property:

Patentable

Region of the country:

Southeast

Current round of investment:

The startup is not looking for investments at the moment



Quantis

Quantis is a platform-type biotech startup developing a pipeline of in vivo regenerative therapies for minimally invasive treatments of human tissues and organs damaged by aging, birth defects or trauma and injuries.

Site:

www.quantis.bio

Solution/Product:

The Human Extracellular Matrix (ECM) produced by Quantis - currently in the pre-clinical validation stage - presents the fundamental structure and composition for inducing local endogenous regeneration, that is, it is both a physical and structural guide and a signal biochemical that stimulates regeneration through the proliferation of cells at the site of damage, inducing guided tissue regeneration.

Intellectual property:

Patent already deposited

Region of the country:

Southeast

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million



Isobio

Isobio is a company focused on the production, qualification and supply of bioactive reference substances. The company has experts in extraction, separation and purification technologies for substances from plants. Carry out the obtaining fractions enriched with a specific composition of phytochemical substances that uniquely meet the objectives of our customers' products or even isolating substances that are not available on the market to meet the needs of researchers and companies.

Site:

www.isobio.com.br

Solution/Product:

Isobio is a technology-based company focused on the production, qualification and supply of bioactive reference substances, through sustainable access to biodiversity and the development of plant-based products, aimed at human health and well-being. Isobio's mission is to produce bioactive molecules that can be applied in the development of innovative products, as well as in pharmacological and toxicological activity tests, quality control of inputs and produce medicines, cosmetics, agricultural and food products.

Intellectual property:

Patentable



Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000



BioUs

We are a deep tech company that developed a technological platform focused on the production of biopolymers from waste from intensive aquaculture and agribusiness production, generating products aligned with nanoparticles and the ESG ecosystem.

Site:

www.bious.com.br

Solution/Product:

Our core science is based on the use of bacteria and yeasts applied in the production of biopolymers and probiotics inoculated in the field and in agriculture.

Intellectual property:

Patent already deposited

Region of the country:

Midwest

Current round of investment:

Seed

Value that the startup is seeking:

US\$ 200.000 to US\$ 1 million

DDM Solutions ‘Data-Driven Minds’

Site:

Solution/Product:

Data analysis combined with artificial intelligence (AI) can have a significant impact in the area of biotechnology, offering several opportunities and benefits, such as accelerating scientific research in discovering new medicines, personalizing medicine, and early diagnosis of diseases with image analysis.

Intellectual property:

Patentable

Region of the country:

Southeast

Current round of investment:

Pre-seed / Angel Investment

Value that the startup is seeking:

Under US\$ 200.000

About companies

Biominas Brasil

Biominas is a pioneer in supporting the structuring of biotechnology and life sciences businesses in Brazil. With the recognition of Minas Gerais as one of the main clusters of biotechnology in Latin America, Biominas celebrates its 34-year legacy in 2024. Since 1990, interacting and developing solutions for researchers, entrepreneurs, medium and large companies, Biominas has focused on promoting entrepreneurship in the transformation of biotechnology science into innovative business. It is the protagonist in a series of programs and activities launched over the last 30 years, including one of the first incubators in the country, the first investment program in nascent companies, studies in the sector, innovative pre-acceleration programs for projects and startups, partnering events, online training courses, among others.

Brazilian Pharmaceutical Innovation Network

The Brazilian Network for Pharmaceutical Innovation was created in February 2020 with the aim of promoting and strengthening the health innovation environment in Brazil. RBIF stands out in a scenario where it works together with government, academia, entrepreneurs, members of society and capital/project financiers to build an innovation ecosystem that enables scientific and technological advances for the Brazilian industry, as well as ensuring the development of the entire pharmaceutical value chain, impacting on the lives of patients and consumers. Organized around 5 main pillars and formalized into 4 important committees, RBIF has free membership for SINDUSFARMA members, in addition to the active participation of other parties interested in innovation, such as government agents and local authorities, entrepreneurs, universities and researchers, as well as representatives of venture capital and development institutions.

Sindusfarma

Founded 90 years ago, in 1933, the pharmaceutical industry association Sindusfarma, the largest entity representing the pharmaceutical industry installed in Brazil, brings together more than 581 national and international companies, of all sizes and specialties, as well as suppliers and service providers. service in the pharmaceutical production chain, which accounts for more than 95% of the medicines market in Brazil and generates approximately 100 thousand direct jobs and 800 thousand indirect jobs.

Among its numerous responsibilities, Sindusfarma maintains a permanent and proactive dialogue with authorities, politicians, experts and society in general, to defend the causes of the pharmaceutical industry installed in the country, in the health, economic, industrial, labor areas, etc. and contribute to improving the public and private health system in the country. The entity also promotes the dissemination of scientific and technological knowledge, with a view to the development of companies in the sector and their professionals and the promotion of health and well-being of the Brazilian population.

Autores

Rosana Mastellaro
Isabela Allende
Marcio de Paula
Raquel Goes

Revisão

Dan Gedankien
João Paulo Amorim
Gerson Almeida

Apoio à produção

Dafne Martins
Jessica Neto

Design Gráfico

Negrilo Produção
Editorial

**Impressão e
acabamento**

AlphaGraphics

**Dados Internacionais de Catalogação na Publicação (CIP)
(Câmara Brasileira do Livro, SP, Brasil)**

Guia brasileiro de startups de biotecnologia em saúde / Raquel Goes... [et al.]; coordenação Rosana Mastellaro. – 1. ed. – São Paulo: Sindicato da Indústria de Produtos Farmacêuticos, 2024.

Outros autores: Isabela Allende, Márcio de Paula, Rosana Mastellaro.

ISBN 978-85-60162-82-6

1. Biotecnologia 2. Indústria farmacêutica – Brasil 3. Startups
I. Goes, Raquel. II. Allende, Isabela. III. Paula, Márcio de. IV. Mastellaro, Rosana.

24-200257

CDD-660.6

Índices para catálogo sistemático:

1. Biotecnologia

660.6

Tábata Alves da Silva – Bibliotecária – CRB-8/9253

Biominas

Av. José Cândido da Silveira, 2100 –
Horto, Belo Horizonte – MG,
CEP 31035 – 536
biominas.org.br

Sindusfarma

São Paulo
Av. Eng. Luís Carlos Berrini, 1681, 5º andar
Brooklin, São Paulo SP, CEP 04571-011

Brasília

Edifício ION
SGAN 601 - Módulo H - Sala 1.089
Asa Norte, Brasília DF, CEP 70830-0181
sindusfarma.org.br

ISBN: 978-85-60162-82-6

